LonosEscape is a room on Stocktwits, a social media platform for investors and traders¹. It is dedicated to long term investing in the small and mid-cap biotech space with a focus on Verastem Inc. (VSTM), a biopharmaceutical company that develops and commercializes medicines for the treatment of cancer. In this blog, I will share some insights and updates about LonosEscape and VSTM based on the web search results from Bing.
Thank you for reading this post, don't forget to subscribe!What is LonosEscape?
LonosEscape is a room created by LonoTrader, a Stocktwits user who has been following VSTM since 2018. He describes himself as a long term investor with a focus on small. The mid-cap biotech companies with strong fundamentals and catalysts.
LonosEscape has 2.4k members who join the room to be a part of the conversation about. VSTM and other biotech stocks the room’s description states: This room is for long term investors in the small and mid-cap biotech space with a focus on VSTM. Moderators. LonoTrader. Style.
The room’s name is a reference to the Hawaiian word Lono, which means peace or prosperity. LonoTrader explains: I chose the name LonosEscape because I wanted to create a peaceful and prosperous. The place for investors who share my vision and passion for biotech.
Why VSTM?
VSTM is the ticker symbol for Verastem, Inc., a company that develops and commercializes medicines for the treatment of cancer. According to its website Verastem’s mission is to improve. The lives of patients fighting cancer by creating medicines that target cancer stem cells.
Verastem’s lead product is COPIKTRA (duvelisib) an oral inhibitor of phosphoinositide 3-kinase (PI3K) which is approve by the FDA. With relapsed or refractory chronic Follicular lymphoma (FL) or lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Verastem is also developing VS-6766, a dual inhibitor of RAF/MEK signaling in combination with defactinib a focal adhesion kinase (FAK) inhibitor, for the treatment of patients with KRAS mutant solid tumors. Verastem has recently announced positive results from its Phase 2 registration-directed trial of VS-6766 and defactinib in patients with low-grade serous ovarian cancer (LGSOC).
LonosEscape members are bullish on VSTM’s prospects, as they believe that the company has a strong pipeline of novel therapies that address unmet medical needs in oncology. They also appreciate the company’s management team, which has extensive experience in biotech and pharma.
What are the latest news and updates?
LonosEscape members are always on the lookout for the latest news and updates about VSTM and other biotech stocks. They use Stocktwits to share their opinions, analysis, research, and predictions. Some of the recent topics discussed in the room are.
- VSTM’s reverse. The stock split announcement on March 25, 2023, which was intended to increase. The market price of its common stock to comply. With the Nasdaq listing requirements The LonosEscape members had mixed reactions to this news, as some saw it as a positive sign of confidence from the management, while others feared it would dilute the value of their shares.
- VSTM’s creation of a direct financial obligation under an off-balance sheet arrangement with Oxford Finance LLC on March 25, 2023, which provided the company with up to $75 million in debt financing to support its clinical development and commercialization activities . LonosEscape members welcomed this news, as they believed it would provide the company with sufficient cash runway to execute its strategy and reach its milestones.
- VSTM’s presentation of updated data from its Phase 2 trial of VS-6766 and defactinib in LGSOC. At the The American Association for Cancer Research (AACR) Annual Meeting 2023 on April 10, 2023, which showed that the combination therapy achieved an overall response rate of 56% and a median progression-free survival of 11 months in patients with KRAS mutant LGSOC. The LonosEscape members were impresse by these results, as they demonstrated the potential of VSTM’s pipeline to address hard-to-treat cancers.
Conclusion
LonosEscape is a room on Stocktwits that provides. The platform for long term investors in the small and mid-cap biotech space, with a focus on VSTM. The room’s members are passionate and knowledgeable about biotech and oncology, and they share their insights and updates about VSTM and other biotech stocks LonosEscape is a place where investors can learn, discuss,. The support each other in their quest for peace and prosperity In the biotech world.
